Newsletter

Pol. Merkur. Lek (Pol. Med. J.), 2020, XLVIII/288: 391-393 Maximize

Pol. Merkur. Lek (Pol. Med. J.), 2020, XLVIII/288: 391-393

Title: Carbon footprint of inhalers in COPD therapy in 2018 and 2019 in Poland in response to the Kigali amendment 

Authors: Płusa T, Badowska-Kozakiewicz AM. 

Version: FULL ARTICLE ONLY IN ENGLISH</p

More details

03/288

0,00 zł

SUMMARY IN POLISH & ENGLISH. FULL ARTICLE ONLY IN ENGLISH.

Carbon footprint of inhalers in COPD therapy in 2018 and 2019 in Poland in response to the Kigali amendment

Płusa T1, Badowska-Kozakiewicz AM2.

1Medical Faculty Lazarski University, Warsaw, Poland; 2Department of Cancer Prevention, Medical University of Warsaw, Poland

The treatment of patients with obstructive airway diseases is based on the use of inhalation preparations. Some of them, mainly including pressurized metered dose inhalers (pMDIs), contain compressed gases – hydrofluoroalkanes, which generate carbon dioxide emissions, creating the so-called carbon footprint.
The aim of the study
was to evaluate the consumption of individual active substances, the types of inhalers used and calculation of the carbon footprint of popular therapies in 2018 and 2019 in Poland.
Material and methods
. The ratio of pMDI vs DPI (dry powder inhaler) data and the data on using long-acting β2-agonists (LABAs), shortacting muscarinic antagonists (SAMAs), long-acting muscarinic antagonists (LAMAs), LAMA+LABAs, LAMA+LABA+ICSs (inhaled corticosteroids) on Polish market during 2018 and 2019 were analyzed. The carbon footprint of such therapies was counted. Then, we studied the reduction of the carbon footprint for scenario A (reducing pMDI by 50%) and scenario B (reducing pMDI by 80%) in the following steps of analysis.
Results
. The general structure of pMDI/DPI in Poland in COPD area was not changed in 2019 vs 2018. The carbon footprint is primarily created by pMDI SAMAs. In 2019 in Poland pMDI SAMAs were 1.6 mio units (the same as in 2018), which generated 33.5 kt CO2e annually, but the whole category generates 40.8 kt CO2e. Scenario A gives us a benefit of 18.8 kt CO2e reduction and scenario B brings us a benefit of 29.9 kt CO2e reduction of emissions.
Conclusions
. Despite Poland’s ratification the Kigali amendment did not affect pMDI consumption and did not reduce the carbon footprint. The lower carbon footprint of DPIs should be considered alongside other factors when choosing inhalation devices.

Key words: carbon footprint, inhalers, COPD

Pol Med J, 2020; XLVIII (288); 391–393